JMD Association for Molecular Pathology 2008 Annual Meeting
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hotakainen, K.
Right arrow Articles by Stenman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hotakainen, K.
Right arrow Articles by Stenman, J.
JMD 2006, Vol. 8, No. 5
Copyright © 2006 American Society for Investigative Pathology & Association for Molecular Pathology

Expression Of Human Chorionic Gonadotropin ß-Subunit Type I Genes Predicts Adverse Outcome In Renal Cell Carcinoma

Kristina Hotakainen*, Susanna Lintula*, Börje Ljungberg{dagger}, Patrik Finne*, Annukka Paju*, Ulf-Håkan Stenman* and Jakob Stenman*{ddagger}

From the Department of Clinical Chemistry; * Helsinki University Central Hospital and Helsinki University, Helsinki, Finland; the Department of Surgical and Perioperative Sciences, Urology and Andrology, {dagger} Umeå University, Umeå, Sweden; and the Department of Surgery, {ddagger} Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland

Expression of the free ß-subunit of human chorionic gonadotropin (hCGß) in malignant tumors is frequently associated with aggressive disease. The pretreatment serum concentration of hCGß is an independent prognostic variable in renal cell carcinoma (RCC). The three so-called type II genes (hCGß 3/9, 5, and 8) have been shown to be up-regulated in relation to type I genes (hCGß 6/7) in some malignant tumors. We developed a reverse transcription-polymerase chain reaction method for quantification of relative levels of the mRNAs for the two types of hCGß genes and studied the association between the expression in RCC tissue (n = 104) and clinical outcome. hCGß mRNA expression was detected in 40% (42 of 104) of the tumors, and in 40 of these (93%), this consisted of hCGß type I mRNA only, whereas type II hCGß mRNA was detected in two samples. hCGß mRNA expression was significantly associated with a shorter disease-specific (log-rank P = 0.023; median survival 1.4 versus 7.9 years) and overall survival (log-rank P = 0.011). In a Cox regression model, stage (P < 0.0001) and hCGß mRNA expression (P < 0.0001) were independent prognostic variables. We conclude that expression of type I hCGß genes indicates adverse prognosis in RCC.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society for Investigative Pathology and the Association for Molecular Pathology.